Bayer AG NA
I · Analyse IA
En bref
Bayer makes prescription medicines for heart disease, women's health, cancer, and blood disorders; sells consumer brands like Midol and Aspirin; and provides seeds, pesticides, and digital farming tools to agriculture customers worldwide [Yahoo Finance]. The Crop Science division is the largest profit contributor, generating nearly half of total revenue [Simply Wall St].
Bayer is a 161-year-old German life sciences giant operating three major divisions: prescription drugs (Pharmaceuticals), over-the-counter health products (Consumer Health), and agricultural seeds and crop chemicals (Crop Science) [Yahoo Finance]. The company currently reports a €2.2 billion net loss on €45.6 billion in revenue, but recent news signals potential recovery through two FDA priority-review drugs in stroke prevention and lung cancer [Yahoo Finance]. Bayer also faces ongoing environmental liabilities, including a recent $133 million settlement for PCB contamination cleanup [Seeking Alpha].
Bayer is currently unprofitable with moderate debt levels, but maintains strong gross margins and positive free cash flow [Yahoo Finance].
Score Sentinellis
4.2/10
Moderate concerns
Capitalisation boursière
EUR 37.8B
Chiffre d'affaires (12 mois)
EUR 45.6B
II · Actualités récentes
Ce qui a fait bouger le cours
6 stories · ranked by relevance
- macro2026-05-20
BAYRY or RHHBY: Which Is the Better Value Stock Right Now?
Zacks
- macro2026-05-20
Should FDA Priority Review for HYRNUO’s First-Line Lung Cancer Use Require Action From Bayer (XTRA:BAYN) Investors?
Yahoo Finance
- macro2026-05-19
Bayer Gets FDA Priority Review for Asundexian NDA in Stroke Prevention
Yahoo Finance
- macro2026-05-19
Bayer Granted Priority Review by U.S. FDA for Asundexian in Patients After a Non-Cardioembolic Ischemic Stroke or Transient Ischemic Attack
Yahoo Finance
- macro2026-05-19
FDA Grants Priority Tag to Bayer's Oncology Drug for First-Line NSCLC
Yahoo Finance
- macro2026-05-17
Assessing Bayer (XTRA:BAYN) Valuation After Mixed Share Performance And Profit Recovery Hopes
Simply Wall St
Premium · gratuit avec tout compte
Bayer reported a €2.2 billion net loss for the most recent fiscal year despite €45.6 billion in revenue, and the company remains unprofitable with a negative net margin of -7.9% [Yahoo Finance]
Risques
5
Opportunités
5
Signaux d'alerte
3
Direction
10
22 autres constats dans le rapport complet — gratuit avec tout compte.
Débloquer l'analyse complète de Bayer AG NA
Créez un compte gratuit pour accéder au rapport complet généré par IA, avec les sources citées dans le texte.
- 5 risques, 5 opportunités et 3 signaux d'alerte — chacun avec sa source
- Plus de 100 indicateurs financiers avec graphiques et comparaisons
- Résumés d'actualités complets avec liens vers les sources
- Équipe dirigeante et rémunération
- Export PDF pour la lecture hors ligne
III · Entreprises similaires
À lire également
Same sector · Healthcare or comparable health
L'ajouter à votre liste ?